Tags

Type your tag names separated by a space and hit enter

Neopterin, a prognostic marker in human malignancies.
Cancer Lett. 2010 Jan 01; 287(1):13-22.CL

Abstract

Increased neopterin concentrations are established in patients with an activated cellular (= Th1-type) immune response which includes allograft rejection, viral infection and autoimmune disorders as well as various malignant tumors. In patients with several types of cancer, neopterin concentrations in body fluids like urine, serum/plasma or ascites parallel the course of the disease, and a higher neopterin concentration in patients is an independent predictor of a shorter survival period. Neopterin is released in large amounts from human monocyte-derived macrophages and dendritic cells preferentially following stimulation with the pro-inflammatory cytokine interferon-gamma, thus reflecting the immune activation status. Therefore, not only as a laboratory diagnostic tool, the measurement of neopterin concentrations allows studying the immunological network and its interaction with the pathogenesis of tumor development. It contributes to a better understanding how immune activation is involved in the development of tumor-induced immune escape and tumor antigen specific tolerance.

Authors+Show Affiliations

Center of Operative Medicine, Department of Visceral, Transplant, and Thoracic Surgery, Innsbruck Medical University, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19500901

Citation

Sucher, Robert, et al. "Neopterin, a Prognostic Marker in Human Malignancies." Cancer Letters, vol. 287, no. 1, 2010, pp. 13-22.
Sucher R, Schroecksnadel K, Weiss G, et al. Neopterin, a prognostic marker in human malignancies. Cancer Lett. 2010;287(1):13-22.
Sucher, R., Schroecksnadel, K., Weiss, G., Margreiter, R., Fuchs, D., & Brandacher, G. (2010). Neopterin, a prognostic marker in human malignancies. Cancer Letters, 287(1), 13-22. https://doi.org/10.1016/j.canlet.2009.05.008
Sucher R, et al. Neopterin, a Prognostic Marker in Human Malignancies. Cancer Lett. 2010 Jan 1;287(1):13-22. PubMed PMID: 19500901.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neopterin, a prognostic marker in human malignancies. AU - Sucher,Robert, AU - Schroecksnadel,Katharina, AU - Weiss,Guenter, AU - Margreiter,Raimund, AU - Fuchs,Dietmar, AU - Brandacher,Gerald, Y1 - 2009/06/04/ PY - 2009/04/08/received PY - 2009/05/09/accepted PY - 2009/6/9/entrez PY - 2009/6/9/pubmed PY - 2010/2/20/medline SP - 13 EP - 22 JF - Cancer letters JO - Cancer Lett. VL - 287 IS - 1 N2 - Increased neopterin concentrations are established in patients with an activated cellular (= Th1-type) immune response which includes allograft rejection, viral infection and autoimmune disorders as well as various malignant tumors. In patients with several types of cancer, neopterin concentrations in body fluids like urine, serum/plasma or ascites parallel the course of the disease, and a higher neopterin concentration in patients is an independent predictor of a shorter survival period. Neopterin is released in large amounts from human monocyte-derived macrophages and dendritic cells preferentially following stimulation with the pro-inflammatory cytokine interferon-gamma, thus reflecting the immune activation status. Therefore, not only as a laboratory diagnostic tool, the measurement of neopterin concentrations allows studying the immunological network and its interaction with the pathogenesis of tumor development. It contributes to a better understanding how immune activation is involved in the development of tumor-induced immune escape and tumor antigen specific tolerance. SN - 1872-7980 UR - https://www.unboundmedicine.com/medline/citation/19500901/Neopterin_a_prognostic_marker_in_human_malignancies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304-3835(09)00346-2 DB - PRIME DP - Unbound Medicine ER -